18:35 EDT Denali Therapeutics (DNLI) trading resumes
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNLI:
- Biogen and Denali’s Parkinson’s candidate did not meet Phase 2b endpoints
- Denali Therapeutics trading halted, news pending
- Biogen CELIA topline readout in Alzheimer’s ‘historic,’ says H.C. Wainwright
- Denali Therapeutics price target lowered to $40 from $42 at Morgan Stanley
- Denali Therapeutics: AVLAYAH Momentum and Pipeline Progress Support Buy Rating, $39 Price Target Maintained